Anti-Citrullinated Peptide Antibodies Control Oral Porphyromonas and Aggregatibacter species in Patients with Rheumatoid Arthritis.
Marina I ArleevskayaEugenia A BoulyginaRegina LarionovaShamil ValidovOlga KravtsovaElena I ShagimardanovaLourdes VeloGeneviève Héry-ArnaudCaroline CarléYves RenaudineauPublished in: International journal of molecular sciences (2022)
Oral microbiome changes take place at the initiation of rheumatoid arthritis (RA); however, questions remain regarding the oral microbiome at pre-RA stages in individuals with clinically suspect arthralgia (CSA). Two cross-sectional cohorts were selected including 84 Tatarstan women (15 early-RA as compared to individuals with CSA ranging from CSA = 0 [ n = 22], CSA = 1 [ n = 19], CSA = 2 [ n = 11], and CSA ≥ 3 [ n = 17]) and 42 women with established RA (median: 5 years from diagnosis [IQ: 2-11]). Amplicon sequence variants (ASVs) obtained from oral samples (16S rRNA) were analyzed for alpha and beta diversity along with the abundance at the genus level. A decrease in oral Porphyromonas sp. is observed in ACPA-positive individuals, and this predominates in early-RA patients as compared to non-RA individuals irrespective of their CSA score. In the RA-established cohort, Porphyromonas sp. and Aggregatibacter sp. reductions were associated with elevated ACPA levels. In contrast, no associations were reported when considering individual, genetic and clinical RA-associated factors. Oral microbiome changes related to the genera implicated in post-translational citrullination ( Porphyromonas sp. and Aggregatibacter sp.) characterized RA patients with elevated ACPA levels, which supports that the role of ACPA in controlling the oral microbiome needs further evaluation.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- cross sectional
- interstitial lung disease
- systemic lupus erythematosus
- end stage renal disease
- magnetic resonance
- type diabetes
- gene expression
- genome wide
- ejection fraction
- metabolic syndrome
- polycystic ovary syndrome
- prognostic factors
- patient reported
- wastewater treatment